Publications by authors named "E Lianidou"
Liquid biopsy enables real-time monitoring of tumor development and response to therapy through the analysis of CTCs and ctDNA. NALCN is a sodium leak channel that is frequently involved in tumor evolution and immunity and acts as a tumor suppressor. Deletion of NALCN has been shown to increase cancer metastasis and the number of CTCs in peripheral blood.
View Article and Find Full Text PDFPlasma cell-free DNA (cfDNA) analysis to track estrogen receptor 1 (ESR1) mutations is highly beneficial for the identification of tumor molecular dynamics and the improvement of personalized treatments for patients with metastatic breast cancer (MBC). Plasma-cfDNA is, up to now, the most frequent liquid biopsy analyte used to evaluate ESR1 mutational status. Circulating tumor cell (CTC) enumeration and molecular characterization analysis provides important clinical information in patients with MBC.
View Article and Find Full Text PDFDirect comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs.
Front Oncol
December 2024
Article Synopsis
- The study compares the effectiveness of ultrasensitive real-time PCR and droplet digital PCR (ddPCR) in detecting specific mutations associated with breast cancer in primary tumors and liquid biopsy samples.
- The research involved analyzing genetic material from 42 tumor samples and 29 plasma samples from patients with ER+ metastatic breast cancer, as well as samples from healthy donors.
- Results showed that both methods provided similar detection rates for certain mutations in tumor samples, with ultrasensitive real-time PCR performing better in plasma-cfDNA samples, indicating potential for non-invasive testing in cancer management.
Article Synopsis
- Lung cancer is a major global health issue, with challenges in early detection and relapse identification; blood-based liquid biopsies show potential in non-invasive monitoring.
- Researchers used a comprehensive approach combining various datasets to identify candidate biomarkers in non-small cell lung cancer (NSCLC), connecting them to specific molecular pathways.
- Results indicated that certain metabolites and RNA expressions in plasma EVs correlate with disease progression and overall survival in NSCLC patients, highlighting their potential as prognostic biomarkers.
Article Synopsis
- The study investigates the genetic landscape of non-small cell lung cancer (NSCLC) and its impact on resistance to osimertinib, using liquid biopsy to identify resistance mechanisms.
- It analyzed plasma-circulating free DNA (cfDNA) and circulating tumor cells (CTCs) from 30 NSCLC patients, detecting various molecular alterations that could indicate resistance to treatment.
- Findings revealed discrepancies in the mutation presence between cfDNA and CTCs, suggesting that combining both analyses provides a broader understanding of resistance and potential treatment options.